Treatment of Advanced or Metastatic Triple-negative Breast Cancer With Adoptive Therapy of PD1+ TILS
Condition(s):Metastatic Triple-Negative Breast CarcinomaLast Updated:November 24, 2023Recruiting
Hide Studies Not Open or Pending
Condition(s):Metastatic Triple-Negative Breast CarcinomaLast Updated:November 24, 2023Recruiting
Condition(s):Metastatic Triple-Negative Breast CarcinomaLast Updated:October 4, 2023Recruiting
Condition(s):Metastatic Triple-Negative Breast CarcinomaLast Updated:April 20, 2022Not yet recruiting
Condition(s):Metastatic Triple-Negative Breast CarcinomaLast Updated:January 28, 2022No longer available
Condition(s):Metastatic Triple-Negative Breast CarcinomaLast Updated:October 11, 2023Recruiting
Condition(s):Anatomic Stage IV Breast Cancer AJCC v8; Metastatic Triple-Negative Breast CarcinomaLast Updated:February 20, 2024Recruiting
Condition(s):Anatomic Stage IV Breast Cancer AJCC v8; Metastatic Triple-Negative Breast CarcinomaLast Updated:November 2, 2023Recruiting
Condition(s):Metastatic HER2-Negative Breast Carcinoma; Metastatic Triple-Negative Breast CarcinomaLast Updated:March 27, 2024Suspended
Condition(s):Metastatic Triple-Negative Breast Carcinoma; Breast CancerLast Updated:November 30, 2023Not yet recruiting
Condition(s):Metastatic Triple-Negative Breast CarcinomaLast Updated:August 19, 2021Approved for marketing
At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.